



Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis

Guest Editor:

Dr. Michal Tomcik

Institute of Rheumatology and
Department of Rheumatology of
the First Faculty of Medicine,
Charles University, Prague, Czech
Republic

Deadline for manuscript
submissions:

closed (30 June 2022)

Message from the Guest Editor

Systemic sclerosis (scleroderma, SSc) is the most enigmatic and challenging of all rheumatic diseases. To date, it is considered incurable and carries the highest cause-specific mortality of all connective tissue diseases. Despite advancements in basic, translational, and clinical research in recent years, the etiology and pathophysiology of this complex and heterogeneous condition remain to be elucidated. Hopefully, novel advancements in these aspects of the management of SSc will contribute to a reduction of suffering and disability and improvement in morbidity and mortality of our patients in the near future.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)